Cancer genomics to understand tumor characteristics and vulnerabilities
Genomic studies have identified new mechanisms that underlie the development of cancer and revealed targets for novel therapies. In addition, systematic genomics allow us to understand the context in which cancer driver mutations occur. Together with transcriptomic and epigenetic analyses, cancer entities are nowadays classified by their molecular features. In addition to the mutated cancer cells, other cellular compartments of solid tumors, including cancer associated fibroblasts and immune cells influence the clinical behavior of cancer patients.
Our lab uses next generation sequencing approaches to characterize cancer on the genomic, transcriptomic and epigenetic level. Using integrative analyses, we try to find molecular patterns that correlate with and potentially explain the different clinical categories of patients. We aim at identifying pathways that are altered in the different compartments of the tumor, including the stroma, that provide potential new targets for intervention.
Dr. rer. nat. Sascha Gromnitza, postdoctoral researcher
Priv.-Doz. Dr. Patrick Plum, Else Kröner Forschungskolleg Cologne fellow
Dr. rer. nat. Oscar Velázquez Camacho, bioinformatics scientist
Dr. (Ph.D.) Christina Wölwer, postdoctoral researcher
Christoph Jonas, PhD student
Marten Wenzel, MD student
Anna-Carina Knufmann, MD student
Vanessa Richartz, technical assistant
German Research Foundation (DFG): “Esophageal adenocarcinoma: understanding the molecular basis of differential treatment response”
Marga und Walter Boll Stiftung: “Funktionelle Charakterisierung von PBX1 im humanen Cholangiokarzinom”